KNE

Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 26, 2024
Diabetic foot, Financial statement, PIN, Ulcer, Symposium, Sale, KNE, Pivot, Credit, Leg, SAWC, US FDA, Patent, FDA, Government, Food

WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results.

Key Points: 
  • WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results.
  • On December 20, 2023, Kane Biotech announced that it received a non-binding offer for its interest in STEM Animal Health.
  • Gross profit for the fourth quarter of 2023 was $398,234, an increase of 24% compared to $320,653 for the fourth quarter ended December 31, 2022.
  • Loss for the fourth quarter of 2023 was ($1,611,894), an increase of 92% compared to ($838,150) for the quarter ended December 31, 2022.

Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health

Retrieved on: 
Wednesday, March 20, 2024
KNE, Sale

WINNIPEG, Manitoba, March 20, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announces today that it has extended the exclusivity period on the offer for its interest in STEM Animal Health that it announced on December 20, 2023, from March 19, 2024 until March 31, 2024.

Key Points: 
  • WINNIPEG, Manitoba, March 20, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announces today that it has extended the exclusivity period on the offer for its interest in STEM Animal Health that it announced on December 20, 2023, from March 19, 2024 until March 31, 2024.
  • Kane further announces that subsequent to the US $625,000 deposit that it received at the time of the offer, Kane has received additional deposits totaling US $900,000 which will be applied towards the sale price of Kane’s interest in STEM.

Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow

Retrieved on: 
Tuesday, March 19, 2024
PIN, KNE, Research, Biofilm, Pharmaceutical industry

Kane Biotech management will host a conference call at 4:30 p.m.

Key Points: 
  • Kane Biotech management will host a conference call at 4:30 p.m.
  • ET to review the financial results and discuss business developments in the period.
  • It is recommended that you join 10 minutes before the event, though you may pre-register at any time.
  • A webcast of the call will be available on the Company's website at www.kanebiotech.com in the Investor section of the Kane Biotech website at ir.kanebiotech.com .

Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award

Retrieved on: 
Friday, March 8, 2024
Biotechnology, Growth, Climate change, KNE, Video game

WINNIPEG, Manitoba, March 08, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the Bioscience Association of Manitoba (“BAM”) annual awards dinner held on March 7, 2024, Kane Biotech received the BAM Company of the Year award.

Key Points: 
  • WINNIPEG, Manitoba, March 08, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the Bioscience Association of Manitoba (“BAM”) annual awards dinner held on March 7, 2024, Kane Biotech received the BAM Company of the Year award.
  • Marc Edwards, President & CEO, accepted the award on behalf of the Company.
  • “We’re very honoured to be the recipient of this prestigious award.
  • The following link includes a video about Kane Biotech that was produced by BAM and presented at the Awards dinner: https://kanebiotech.com/#videos

Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair

Retrieved on: 
Thursday, February 22, 2024
Theta, Doctor of Philosophy, Catheter, FDA, University, Food, Sigma Theta Tau, Skin care, Leadership studies, Nephrology, Executive, KNE, Management

WINNIPEG, Manitoba, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the special meeting of the shareholders of the Company held on February 20, 2024, Dr. Robert Huizinga was elected as a director of the Company.

Key Points: 
  • WINNIPEG, Manitoba, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the special meeting of the shareholders of the Company held on February 20, 2024, Dr. Robert Huizinga was elected as a director of the Company.
  • Mr. Huizinga has also been appointed by the directors of the Company as Executive Chair of the Company.
  • Dr. Huizinga has been a member of Kane Biotech’s Scientific Advisory Board since 2018.
  • “I’m excited that the Board accepted my recommendation to add Robert to the Board and to appoint him to the Executive Chair role,” said Marc Edwards, President & Chief Executive Officer.

Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel Spray

Retrieved on: 
Wednesday, January 31, 2024
Burn, Pain, FDA, Skin, Water, Risk, Infection, Wound healing, Patent, Burns, KNE, Cosmetics

WINNIPEG, Manitoba, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that it has filed a patent on its revyve™ Antimicrobial Wound Gel Spray, a follow-on product to its FDA 510(k) cleared revyve™ Antimicrobial Wound Gel, and will be introducing it today at the Boswick Burn and Wound Care Symposium.

Key Points: 
  • WINNIPEG, Manitoba, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that it has filed a patent on its revyve™ Antimicrobial Wound Gel Spray, a follow-on product to its FDA 510(k) cleared revyve™ Antimicrobial Wound Gel, and will be introducing it today at the Boswick Burn and Wound Care Symposium.
  • “Kane has taken their revyve™ Antimicrobial Wound Gel and loaded it into this new, patent-pending delivery system creating a highly differentiated product ideal for burns and other sensitive wounds”, stated Dr. Gregory Schultz, Chief Scientific Officer of Kane Biotech.
  • “The spray application makes it very easy to apply to the wound, and its thermo-reversible properties allow the gel to adhere to the skin on contact and makes it very easy to rinse off with cool water.
  • “We believe this new application system with its optimum spray pattern, will have such a significant impact on treating sensitive wounds, in particular burns, that Kane has filed a patent”, said Marc Edwards, Chief Executive Officer of Kane Biotech.

Kane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium

Retrieved on: 
Thursday, January 25, 2024
Burns, KNE, Infection, Wound healing, PHMB, Poloxamer

WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium.

Key Points: 
  • WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium.
  • The international conference will take place from January 27 to February 1, 2024 in Maui, Hawaii and covers the latest advancements in wound healing, burn care, and infection control.
  • During this conference, Kane Biotech will present along with other important voices involved in the care of soft tissue injuries and related complications.
  • “I’m excited to be presenting Kane’s revyve™ Antimicrobial Wound Gel to the wound care community at the Boswick conference and believe it will be very well-received, particularly by practitioners focused on burn care.

Kane Biotech Announces Special Meeting of Shareholders

Retrieved on: 
Thursday, January 18, 2024
Theta, Nephrology, Meeting, University, Executive, Leadership studies, Doctor of Philosophy, Sigma Theta Tau, KNE

WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the “Meeting”) to consider the election of Dr. Robert Huizinga as an additional director of the Company.

Key Points: 
  • WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the “Meeting”) to consider the election of Dr. Robert Huizinga as an additional director of the Company.
  • The information circular and other materials with respect to the Meeting will be filed on SEDAR+ by the Company in due course.
  • Dr. Huizinga holds a PhD in Organizational Leadership, a Masters in Clinical Epidemiology, holds his Nephrology certification and is a member of Sigma Theta Tau.
  • Dr. Huizinga has been a member of Kane Biotech’s Scientific Advisory Board since 2018.

Kane Biotech Announces Correction to Press Release

Retrieved on: 
Friday, December 29, 2023
KNE

WINNIPEG, Manitoba, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) today announces a correction to its press release dated December 28, 2023.

Key Points: 
  • WINNIPEG, Manitoba, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) today announces a correction to its press release dated December 28, 2023.
  • The maturity date of the Company’s amended and restated credit facility between Pivot I Financial Limited Partnership and the Company dated August 31, 2021, as amended, has been extended to March 31, 2024, not March 31, 2023 as stated in the release.

Kane Biotech Announces Amendment to its Credit Facility

Retrieved on: 
Thursday, December 28, 2023
Pivot, Line of credit, TSX Venture Exchange, KNE, Credit

WINNIPEG, Manitoba, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on December 20, 2023, the Company and Pivot I Financial Limited Partnership (“Pivot”) entered into a definitive agreement to amend the terms of the Company’s amended and restated credit facility between Pivot and the Company dated August 31, 2021, as amended (the “Credit Facility”) by extending the maturity date of the Credit Facility from November 30, 2023 to March 31, 2023.

Key Points: 
  • WINNIPEG, Manitoba, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on December 20, 2023, the Company and Pivot I Financial Limited Partnership (“Pivot”) entered into a definitive agreement to amend the terms of the Company’s amended and restated credit facility between Pivot and the Company dated August 31, 2021, as amended (the “Credit Facility”) by extending the maturity date of the Credit Facility from November 30, 2023 to March 31, 2023.
  • In addition, the parties agreed that from December 1, 2023 until maturity, interest accrued on each advance under the Credit Facility thereafter shall be payable monthly in arrears rather than being added to the principal amount of the Credit Facility and repaid at maturity.
  • “I would like to thank Pivot for their ongoing support of Kane,” said Ray Dupuis, Chief Financial Officer.
  • “The extension of the Credit Facility maturity date will allow us to work toward closing on a binding share purchase agreement with respect to the offer it has received for its interest in STEM Animal Health, which the Company announced on December 20, 2023.”
    The amendment to the Credit Facility remains subject to the final approval of the TSX Venture Exchange.